FDA Formally Rejects Aradigm's Linhaliq, Requests a New Phase III Trial for Reconsideration

the FDA has determined that it cannot approve the NDA in its present form and provides specific reasons for this action along with recommendations needed for resubmission.
Source: BioSpace